Foghorn Therapeutics Inc. (Nasdaq: FHTX) has received positive news from the U.S. Food and Drug Administration (FDA) as the clinical hold on the Phase 1 monotherapy dose escalation study of FHD-286 in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) has been lifted. 

This development paves the way for Foghorn to progress with their plans for a Phase 1 study of FHD-286 in combination with decitabine or cytarabine for relapsed and/or refractory AML patients. Anticipated to commence in the third quarter of 2023, this study aims to explore potential treatment options further. 

$FHTX experienced an 18.31% pre-market increase, reaching $8.40, following the announcement

BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) has expanded its collaboration with the Max Planck Society and the University Medical Center Gottingen (UMG) through an exclusive worldwide license agreement to develop and commercialize VHH antibodies (NanoAbs) targeting Interleukin-17 (IL-17) for various indications, starting with psoriasis and psoriatic arthritis.

The market responded positively to this news, as $BVXV witnessed a pre-market increase to $2.31 (+34.30%).

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) has shared the results of its pivotal Phase 3 REBUILD clinical trial, which assessed the safety and efficacy of INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD). 

Unfortunately, the trial did not meet its primary endpoint concerning the change in moderate to vigorous physical activity. In fact, iNO45 performed worse than the placebo in this regard by 5.49 minutes per day (p=0.2646).

As a consequence of these findings, $BLPH experienced a significant decline in pre-market trading, reaching $1.98 and reflecting a decrease of 71.95%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)